Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells
- PMID: 23846725
- PMCID: PMC3742245
- DOI: 10.3390/ijms140714301
Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells
Abstract
Despite the high prevalence of histological Benign Prostatic Hypeplasia (BPH) in elderly men, little is known regarding the molecular mechanisms and networks underlying the development and progression of the disease. Here, we explored the effects of a phytotherapeutic agent, Lipidosterolic extract of the dwarf palm plant Serenoa repens (LSESr), on the mRNA gene expression profiles of two representative models of BPH, BPH1 cell line and primary stromal cells derived from BPH. Treatment of these cells with LSESr significantly altered gene expression patterns as assessed by comparative gene expression profiling on gene chip arrays. The expression changes were manifested three hours following in vitro administration of LSESr, suggesting a rapid action for this compound. Among the genes most consistently affected by LSESr treatment, we found numerous genes that were categorized as part of proliferative, apoptotic, and inflammatory pathways. Validation studies using quantitative real-time PCR confirmed the deregulation of genes known to exhibit key roles in these biological processes including IL1B, IL1A, CXCL6, IL1R1, PTGS2, ALOX5, GAS1, PHLDA1, IL6, IL8, NFkBIZ, NFKB1, TFRC, JUN, CDKN1B, and ERBB3. Subsequent analyses also indicated that LSESr treatment can impede the stimulatory effects of certain proinflammatory cytokines such as IL6, IL17, and IL15 in these cells. These results suggest that LSESr may be useful to treat BPH that manifest inflammation characteristics. This also supports a role for inflammation in BPH presumably by mediating the balance between apoptosis and proliferation.
Figures







Similar articles
-
Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia.Prostate. 2015 May;75(7):706-22. doi: 10.1002/pros.22953. Epub 2015 Feb 14. Prostate. 2015. PMID: 25683150
-
Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.BJU Int. 2012 Sep;110(6 Pt B):E301-7. doi: 10.1111/j.1464-410X.2012.11144.x. Epub 2012 Apr 23. BJU Int. 2012. PMID: 22520557
-
Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.Drugs Aging. 1996 Nov;9(5):379-95. doi: 10.2165/00002512-199609050-00008. Drugs Aging. 1996. PMID: 8922564 Review.
-
Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia.Prostate. 2000 Nov 1;45(3):259-66. doi: 10.1002/1097-0045(20001101)45:3<259::aid-pros9>3.0.co;2-g. Prostate. 2000. PMID: 11074529
-
Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.J Urol. 2004 Nov;172(5 Pt 1):1792-9. doi: 10.1097/01.ju.0000140503.11467.8e. J Urol. 2004. PMID: 15540722 Review.
Cited by
-
New Natural Pigment Fraction Isolated from Saw Palmetto: Potential for Adjuvant Therapy of Hepatocellular Carcinoma.Int J Mol Sci. 2016 Aug 5;17(8):1277. doi: 10.3390/ijms17081277. Int J Mol Sci. 2016. PMID: 27527161 Free PMC article.
-
Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms.BMC Urol. 2014 Aug 11;14:63. doi: 10.1186/1471-2490-14-63. BMC Urol. 2014. PMID: 25112532 Free PMC article. Review.
-
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.Int J Mol Sci. 2016 Aug 11;17(8):1311. doi: 10.3390/ijms17081311. Int J Mol Sci. 2016. PMID: 27529214 Free PMC article. Review.
-
Phytotherapy for Benign Prostatic Hyperplasia.Curr Urol Rep. 2016 Jul;17(7):53. doi: 10.1007/s11934-016-0609-z. Curr Urol Rep. 2016. PMID: 27180172 Review.
-
Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients.Sci Rep. 2021 Sep 29;11(1):19401. doi: 10.1038/s41598-021-98586-5. Sci Rep. 2021. PMID: 34588509 Free PMC article.
References
-
- Carter H.B., Coffey D.S. The prostate: An increasing medical problem. Prostate. 1990;16:39–48. - PubMed
-
- Lee K.L., Peehl D.M. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J. Urol. 2004;172:1784–1791. - PubMed
-
- Kramer G., Mitteregger D., Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur. Urol. 2007;51:1202–1216. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous